Third Harmonic BioTHRD
THRD
About: Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.
Employees: 31
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
262% more call options, than puts
Call options by funds: $286K | Put options by funds: $79K
177% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 13
50% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 3 (+1) [Q1 2025]
14% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 29
3% more funds holding
Funds holding: 96 [Q4 2024] → 99 (+3) [Q1 2025]
13.83% less ownership
Funds ownership: 99.76% [Q4 2024] → 85.93% (-13.83%) [Q1 2025]
71% less capital invested
Capital invested by funds: $463M [Q4 2024] → $134M (-$328M) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$5
8%
downside
Avg. target
$5
8%
downside
High target
$5
8%
downside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
Stifel Alex Thompson | 8%downside $5 | Hold Downgraded | 28 Mar 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
3 days ago
Third Harmonic Bio Announces Stockholder Approval of Plan of Liquidation and Dissolution, Updated THB335 Phase 1 Clinical Data, and Initiation of Sale of THB335
Stockholders overwhelmingly approved liquidation and dissolution of the Company at the June 5, 2025 Annual Meeting Initial distribution currently expected in the range between approximately $5.30 and $5.35 per share of common stock, expected in the third quarter of 2025 THB335 demonstrated 85% serum tryptase reduction with an encouraging safety profile in an additional Phase 1 cohort evaluating 100mg dose with new drug product capsule formulation Company initiating a sale process of THB335 SAN FRANCISCO, June 12, 2025 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD) today announced that its stockholders overwhelmingly approved the previously proposed Plan of Liquidation and Dissolution (the “Plan of Dissolution”) at the Company's Annual Meeting of Stockholders held on June 5, 2025. In addition, The Company also announced the results of a recently completed additional cohort in its Phase 1 clinical trial of its oral wild-type KIT inhibitor development candidate, THB335, and that it is initiating the sale process of THB335 as part of the Plan of Dissolution.
Neutral
GlobeNewsWire
2 months ago
Third Harmonic Bio Announces Plan of Liquidation and Dissolution
Board of Directors has approved plan to liquidate and intends to seek stockholder approval for dissolution of the Company at the Annual Meeting of Stockholders on June 5, 2025
Neutral
GlobeNewsWire
2 months ago
Third Harmonic Bio Announces Fourth Quarter and Full Year 2024 Financial Results
Recently presented THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU)
Negative
Zacks Investment Research
3 months ago
Third Harmonic Bio, Inc. (THRD) Loses -31.61% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Third Harmonic Bio, Inc. (THRD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Positive
Zacks Investment Research
3 months ago
Third Harmonic Bio, Inc. (THRD) Upgraded to Buy: What Does It Mean for the Stock?
Third Harmonic Bio, Inc. (THRD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Positive
Zacks Investment Research
3 months ago
Down -39.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Third Harmonic Bio, Inc. (THRD)
The heavy selling pressure might have exhausted for Third Harmonic Bio, Inc. (THRD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Negative
Benzinga
4 months ago
Third Harmonic Bio Initiates Strategic Review, Lays Off 50% Staff Citing Competitive Landscape
On Tuesday, Third Harmonic Bio, Inc. THRD revealed results from its Phase 1 single and multiple ascending dose (SAD/MAD) trial of THB335 in healthy volunteers.
Neutral
GlobeNewsWire
4 months ago
Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate Strategic Update
THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU) Company initiating process to leverage balance sheet strength to maximize shareholder value Cash and cash equivalents of approximately $285 million as of December 31, 2024 (unaudited) Management to hold conference call/webcast today Tuesday, February 11, 2025, at 8:00 a.m. EST to discuss clinical results and corporate next steps SAN FRANCISCO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced results from its Phase 1 single and multiple ascending dose (SAD/MAD) clinical trial of THB335 in healthy volunteers.
Neutral
GlobeNewsWire
6 months ago
Third Harmonic Bio to Participate in the 7th Annual Evercore HealthCONx Conference
SAN FRANCISCO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that Chris Murphy, Chief Financial and Business Officer, will participate in a fireside chat at the 7th Annual Evercore HealthCONx Conference on Wednesday, December 4, 2024, at 9:35 a.m.
Positive
Zacks Investment Research
7 months ago
Wall Street Analysts Believe Third Harmonic Bio, Inc. (THRD) Could Rally 26.67%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 26.7% in Third Harmonic Bio, Inc. (THRD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Charts implemented using Lightweight Charts™